Seneca Biopharma Logo
US81689B1035

Seneca Biopharma

Ins Portfolio
60% Chancen, 40% Gelassenheit. Aktien und Anleihen in einem LifeStrategy ETF. Jetzt entdecken
Anzeige

Kurse werden geladen...

 Anzeige

Prognose

Das durchschnittliche Kursziel der Analysten beträgt +1,32(+116,39%). Der Median liegt bei +1,32(+116,39%).

Kaufen
  3
Halten
  0
Verkaufen
  0

Scoring-Modelle

Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.

News


  • Palisade Bio Reports Positive Phase 1a Results for PALI-2108, a First-in-Class Terminal Ileum and Colon-Targeted PDE4 B/D Inhibitor for Fibrostenotic Crohn's Disease and Ulcerative Colitis

    Study met its primary endpoints of safety, tolerability, and pharmacokinetics (PK)  No serious adverse events (SAEs) or treatment-emergent adverse events (TEAEs) related to laboratory values or EKGs observed across SAD/MAD cohorts Management releases a “What This Means” segment discussing the topline Phase 1a data; Access here Carlsbad, CA, May 27, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced positive topline results from its completed Phase 1 studies of PALI-2108, a novel, locally-activated, terminal ileum and colon-targeted phosphodiesterase-4 B/D (PDE4 B/D) inhibitor being developed for fibrostenotic Crohn's disease (FSCD) and moderate to severe ulcerative colitis (UC). Additionally, the Company announced the release of a Virtual Investor “What This Means” segment to discuss the topline data, which is now available here.» Mehr auf globenewswire.com


  • Palisade Bio Presents Positive Preclinical Data Highlighting Potential of PALI-2108 as a Promising Colon-Specific PDE4 Inhibitor for the Treatment of Ulcerative Colitis and Other Inflammatory Bowel Diseases

    Two posters presented at Digestive Disease Week (DDW) 2025 Preclinical results indicate that PALI-2108 effectively modulates inflammatory pathways in the colon, promoting a favorable immune response Company advancing Phase 1a/b study of PALI-2108 and has demonstrated a favorable safety profile in single-ascending-dose cohorts Carlsbad, CA, May 06, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced the presentation of positive preclinical data from PALI-2108, an orally administered, colon-specific phosphodiesterase-4 (PDE4) inhibitor prodrug in development for patients with ulcerative colitis (UC). The presented data highlighted the efficacy and safety profile of PALI-2108 in a mouse model of colitis, with a particular focus on its impact on PDE4B expression, cAMP levels, and TNF-α suppression as well as predicting efficacious PALI-0008 levels in patients.» Mehr auf globenewswire.com


  • Palisade Bio's AI-Driven Approach to IBD Heterogeneity and Efficacy Selected for Presentation at the 3rd Annual Precision Medicine in Inflammatory Bowel Disease Summit

    Carlsbad, CA, May 01, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that it has been selected to give an oral presentation at the 3 rd Annual Precision Medicine in Inflammatory Bowel Disease Summit being held May 13–15, 2025 in Boston, MA.» Mehr auf globenewswire.com

Unternehmenszahlen

Im letzten Quartal hatte Seneca Biopharma einen Umsatz von 0,00 und ein Nettoeinkommen von 2,06 Mio
(EUR)März 2025
YOY
Umsatz0,00-
Bruttoeinkommen0,00100,00%
Nettoeinkommen2,06 Mio36,92%
EBITDA2,14 Mio34,62%

Fundamentaldaten

MetrikWert
Marktkapitalisierung
+2,86 Mio
Anzahl Aktien
4,80 Mio
52 Wochen-Hoch/Tief
+4,52 - +0,53
DividendenNein
Beta
1,34
KGV (PE Ratio)
0,25
KGWV (PEG Ratio)
0,04
KBV (PB Ratio)
+0,61
KUV (PS Ratio)
0,00

Unternehmensprofil

Palisade Bio, Inc. ist ein biopharmazeutisches Unternehmen im klinischen Stadium, das sich auf die Entdeckung, Entwicklung und Vermarktung von oralen Therapien konzentriert, die auf schwere Krankheiten abzielen, die mit dem Zusammenbruch der Schleimhautbarriere zum Schutz des Magen-Darm-Trakts verbunden sind. Sein führender therapeutischer Kandidat ist LB1148, eine orale Flüssigformulierung des Verdauungsenzyms Inhibitor, der die Aktivität von Verdauungsenzymen hemmen und die Integrität des Darms bei Stress, wie z. B. bei verminderter Durchblutung des Darms, Infektionen und Operationen, erhalten soll. Das Unternehmen wurde 2005 gegründet und hat seinen Hauptsitz in Carlsbad, Kalifornien.

Name
Seneca Biopharma
CEO
J. D. Finley
SitzCarlsbad, ca
USA
Website
Börsengang
Mitarbeiter8

Ticker Symbole

BörseSymbol
NASDAQ
PALI
🍪

Parqet nutzt Cookies.Erfahre Mehr